Condition: Pancreatic Neuroendocrine Tumors, WHO Grade I-II · Sponsor: Oslo University Hospital
A national multicenter prospective study to investigate the feasibility and efficacy of endoscopic ultrasound guided radiofrequency ablation of neuroendocrine pancreatic tumors, WHO Grade 1-2 of 3 cm or less in diameter.
This description comes directly from the study's public registry record.
Espen Thiis-Evensen, MD, PhD · 45039399 · ethiisev@ous-hf.no
Jon Sponheim, MD. PhD · 99029509 · jsponh@ous-hf.no
Always discuss trial participation with your own doctor first.
| Oslo University Hospital | Oslo, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05243082